| scholarly article | Q13442814 |
| P356 | DOI | 10.1038/NCHEMBIO.2528 |
| P8608 | Fatcat ID | release_3qxi4ah4orgy5kdf4loqfyjsr4 |
| P698 | PubMed publication ID | 29200206 |
| P50 | author | Timothy Harrison | Q96207063 |
| P2093 | author name string | Caroline Hughes | |
| Matthew D Helm | |||
| Natalie Page | |||
| Oliver Barker | |||
| Colin R O'Dowd | |||
| Hugues Miel | |||
| Ewa Odrzywol | |||
| Keeva McClelland | |||
| Jakub Flasz | |||
| Anthony Dossang | |||
| Eamon Cassidy | |||
| Elias Arkoudis | |||
| Gerald Gavory | |||
| P2860 | cites work | FOXO4 transcriptional activity is regulated by monoubiquitination and USP7/HAUSP | Q24302269 |
| PHENIX: a comprehensive Python-based system for macromolecular structure solution | Q24654617 | ||
| Drugging the undruggables: exploring the ubiquitin system for drug development | Q26752823 | ||
| MDM2 small-molecule antagonist RG7112 activates p53 signaling and regresses human tumors in preclinical cancer models | Q27683975 | ||
| Refinement of macromolecular structures by the maximum-likelihood method | Q27861011 | ||
| Features and development of Coot | Q27861079 | ||
| MINDY-1 Is a Member of an Evolutionarily Conserved and Structurally Distinct New Family of Deubiquitinating Enzymes. | Q27934744 | ||
| Dysregulation of Ubiquitin-Proteasome System in Neurodegenerative Diseases | Q28073686 | ||
| Modulation of the p53/MDM2 interplay by HAUSP inhibitors | Q28075457 | ||
| Clinical use of proteasome inhibitors in the treatment of multiple myeloma | Q28080999 | ||
| Tumour suppression: disruption of HAUSP gene stabilizes p53 | Q28254102 | ||
| Dissection of USP catalytic domains reveals five common insertion points | Q28257711 | ||
| Protein profiling with Epstein-Barr nuclear antigen-1 reveals an interaction with the herpesvirus-associated ubiquitin-specific protease HAUSP/USP7. | Q30941966 | ||
| A noncovalent class of papain-like protease/deubiquitinase inhibitors blocks SARS virus replication | Q33375590 | ||
| USP7 attenuates hepatic gluconeogenesis through modulation of FoxO1 gene promoter occupancy. | Q33701405 | ||
| Inactivation of HAUSP in vivo modulates p53 function | Q33802926 | ||
| Stabilization of the transcription factor Foxp3 by the deubiquitinase USP7 increases Treg-cell-suppressive capacity. | Q34049065 | ||
| Discovery of specific inhibitors of human USP7/HAUSP deubiquitinating enzyme | Q34240760 | ||
| SAR405838: an optimized inhibitor of MDM2-p53 interaction that induces complete and durable tumor regression | Q34584722 | ||
| Development of inhibitors in the ubiquitination cascade | Q35044801 | ||
| Screening of DUB activity and specificity by MALDI-TOF mass spectrometry | Q35232335 | ||
| Inhibiting the deubiquitinating enzymes (DUBs). | Q35386992 | ||
| The ubiquitin-specific protease USP7 modulates the replication of Kaposi's sarcoma-associated herpesvirus latent episomal DNA | Q36086767 | ||
| Deubiquitination of Ci/Gli by Usp7/HAUSP Regulates Hedgehog Signaling | Q36232579 | ||
| Reversible inactivation of deubiquitinases by reactive oxygen species in vitro and in cells. | Q36737013 | ||
| Stabilization of histone demethylase PHF8 by USP7 promotes breast carcinogenesis | Q36951802 | ||
| HAUSP deubiquitinates and stabilizes N-Myc in neuroblastoma | Q37387937 | ||
| K63-polyubiquitinated HAUSP deubiquitinates HIF-1α and dictates H3K56 acetylation promoting hypoxia-induced tumour progression | Q37500984 | ||
| The multifaceted roles of USP7: new therapeutic opportunities | Q37862125 | ||
| Biophysical and computational fragment-based approaches to targeting protein-protein interactions: applications in structure-guided drug discovery | Q38042773 | ||
| Deubiquitylases from genes to organism | Q38125278 | ||
| Selective and reversible inhibitors of ubiquitin-specific protease 7: a patent evaluation (WO2013030218). | Q38181181 | ||
| Emerging potential of therapeutic targeting of ubiquitin-specific proteases in the treatment of cancer. | Q38244793 | ||
| Deubiquitinase inhibition as a cancer therapeutic strategy | Q38274749 | ||
| DUBs, the regulation of cell identity and disease | Q38336126 | ||
| Recent Advances in the Discovery of Deubiquitinating Enzyme Inhibitors | Q38725385 | ||
| The increasing complexity of the ubiquitin code | Q38845500 | ||
| Activity-based chemical proteomics accelerates inhibitor development for deubiquitylating enzymes | Q39437160 | ||
| Enzymatic characterisation of USP7 deubiquitinating activity and inhibition | Q39563641 | ||
| Selective Dual Inhibitors of the Cancer-Related Deubiquitylating Proteases USP7 and USP47. | Q39730830 | ||
| Small-molecule inhibitor of USP7/HAUSP ubiquitin protease stabilizes and activates p53 in cells | Q39813804 | ||
| The deubiquitinylation and localization of PTEN are regulated by a HAUSP-PML network | Q39948774 | ||
| HAUSP is required for p53 destabilization | Q40561105 | ||
| Characterization of selective ubiquitin and ubiquitin-like protease inhibitors using a fluorescence-based multiplex assay format | Q41837023 | ||
| Herpes simplex virus type 1 immediate-early protein Vmw110 binds strongly and specifically to a 135-kDa cellular protein | Q45778575 | ||
| USP7 small-molecule inhibitors interfere with ubiquitin binding | Q46429336 | ||
| Structure-Guided Development of a Potent and Selective Non-covalent Active-Site Inhibitor of USP7. | Q47619828 | ||
| Molecular basis of USP7 inhibition by selective small-molecule inhibitors | Q47633676 | ||
| Chemical Approaches to Intervening in Ubiquitin Specific Protease 7 (USP7) Function for Oncology and Immune Oncology Therapies. | Q48304688 | ||
| Synthesis and biological evaluation of thiazole derivatives as novel USP7 inhibitors. | Q51177627 | ||
| Drug makers target ubiquitin proteasome pathway anew. | Q53444544 | ||
| A simple assay for detection of small-molecule redox activity | Q80500207 | ||
| P433 | issue | 2 | |
| P921 | main subject | allosteric inhibitor | Q70361704 |
| P304 | page(s) | 118-125 | |
| P577 | publication date | 2017-12-04 | |
| P1433 | published in | Nature Chemical Biology | Q904026 |
| P1476 | title | Discovery and characterization of highly potent and selective allosteric USP7 inhibitors | |
| P478 | volume | 14 |
| Q92190940 | A High-Throughput Assay for Monitoring Ubiquitination in Real Time |
| Q100671973 | An Integrated In Silico Approach and In Vitro Study for the Discovery of USP7 Small Molecule Inhibitors as Potential Cancer Therapies |
| Q63384377 | Breaking the chains: deubiquitylating enzyme specificity begets function |
| Q59798588 | Chemically Induced Cellular Proteolysis: An Emerging Therapeutic Strategy for Undruggable Targets |
| Q90293202 | Comprehensive Landscape of Active Deubiquitinating Enzymes Profiled by Advanced Chemoproteomics |
| Q90088711 | Deubiquitinases: Pro-oncogenic Activity and Therapeutic Targeting in Blood Malignancies |
| Q90350830 | Diarylcarbonates are a new class of deubiquitinating enzyme inhibitor |
| Q50026699 | Drug development: Allosteric inhibitors hit USP7 hard |
| Q92240507 | Emerging drug development technologies targeting ubiquitination for cancer therapeutics |
| Q92233301 | Evaluating enzyme activities and structures of DUBs |
| Q61570969 | Genome-scale CRISPR-Cas9 screen identifies druggable dependencies in wild-type Ewing sarcoma |
| Q58116151 | Identification and Characterization of USP7 Targets in Cancer Cells |
| Q52655073 | Identification and Structure-Guided Development of Pyrimidinone Based USP7 Inhibitors. |
| Q91923645 | Inhibition of p53 inhibitors: progress, challenges and perspectives |
| Q95648224 | Inhibition of ubiquitin-specific protease 7 sensitizes acute myeloid leukemia to chemotherapy |
| Q100490721 | Many small steps towards a COVID-19 drug |
| Q92529034 | Nuclear deubiquitination in the spotlight: the multifaceted nature of USP7 biology in disease |
| Q89598452 | Proteasome Inhibitors: Harnessing Proteostasis to Combat Disease |
| Q90669066 | Seeking Convergence and Cure with New Myeloma Therapies |
| Q91737916 | Small molecule inhibitors reveal allosteric regulation of USP14 via steric blockade |
| Q90505741 | Small molecules that target the ubiquitin system |
| Q57175210 | Structural Basis of Substrate Recognition and Covalent Inhibition of Cdu1 from Chlamydia trachomatis |
| Q92002855 | Targeting USP7-Mediated Deubiquitination of MDM2/MDMX-p53 Pathway for Cancer Therapy: Are We There Yet? |
| Q106996591 | The complex structure of GRL0617 and SARS-CoV-2 PLpro reveals a hot spot for antiviral drug discovery |
| Q64288182 | The role of ubiquitin-specific peptidases in cancer progression |
| Q64109748 | The ubiquitin interacting motifs of USP37 act on the proximal Ub of a di-Ub chain to enhance catalytic efficiency |
| Q61816131 | USP7 Cooperates with NOTCH1 to Drive the Oncogenic Transcriptional Program in T-Cell Leukemia |
| Q98771728 | USP7 Is a Master Regulator of Genome Stability |
| Q63246433 | USP7 Regulates Cytokinesis through FBXO38 and KIF20B |
| Q90100499 | USP7 inhibits Wnt/β-catenin signaling through promoting stabilization of Axin |
| Q89737230 | USP7 stabilizes EZH2 and enhances cancer malignant progression |
| Q91936479 | USP7: Structure, substrate specificity, and inhibition |
| Q64389021 | Ubiquitin-specific protease 7 sustains DNA damage response and promotes cervical carcinogenesis |
Search more.